Coexisting of hearing loss and chronic myeloid leukemia: A systematic literature review
Data files
Jul 22, 2024 version files 6.08 KB
-
README.md
3.09 KB
-
Research_Data.csv
2.99 KB
Abstract
Objective: This systematic literature review aimed to study the relationship between CML and hearing loss.
Database review: Chronic myeloid leukemia (CML) is a hematological malignancy associated with high levels of white blood cells (WBCs). Changes in otolaryngology are observed in CML.
Methodology: This systematic literature review of the literature was conducted by searching the MEDLINE/PubMed, Scopus, WPRIM, LILAC Sand SciELO databases. Studies published between 2013 and 2023 that met inclusion criteria were included. The Joanna Briggs Institute (JBI) Critical Appraisal Checklist was used to evaluate the quality of studies.
Results: Of the 142 identified articles, 13 were included for final evaluation with a total sample size of 75 cases diagnosed with CML with hearing defect. CML patients with WBCs above 250 x 109/L were at higher risk of ototoxicity. Males accounted for 85% of cases; with a mean age of 38.9 years. Hearing loss as the first manifestation of CML was among 61.5% of cases, it was bilateral in 83.3% of cases, and in 90% of cases were irreversible defect.
Conclusion: Acute sudden hearing loss has been associated with high levels of WBC in patients with CML. Neither aggressive leukoreduction nor leukapheresis has positive effect on the reversibility of the hearing loss.
https://doi.org/10.5061/dryad.ngf1vhj35
This systematic literature review aimed to study the relationship between CML and hearing loss. Chronic myeloid leukemia (CML) is a hematological malignancy associated with high levels of white blood cells (WBCs). Changes in otolaryngology are observed in CML. This systematic literature review of the literature was conducted by searching the MEDLINE/PubMed, Scopus, WPRIM, LILAC Sand SciELO databases. Studies published between 2013 and 2023 that met inclusion criteria were included. The Joanna Briggs Institute (JBI) Critical Appraisal Checklist was used to evaluate the quality of studies. Of the 142 identified articles, 13 were included for final evaluation with a total sample size of 75 cases diagnosed with CML with hearing defect. CML patients with WBCs above 250 x 109/L were at higher risk of ototoxicity. Males accounted for 85% of cases; with a mean age of 38.9 years. Hearing loss as the first manifestation of CML was among 61.5% of cases, it was bilateral in 83.3% of cases, and in 90% of cases were irreversible defect. In conclusion, acute sudden hearing loss has been associated with high levels of WBC in patients with CML. Neither aggressive leukoreduction nor leukapheresis has positive effect on the reversibility of the hearing loss.
Description of the data and file structure
The database was searched between January 3rd, 2023 to July 22, 2023. The search and report process followed the statement and flowchart of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).Scientific articles published and available in scientific databases in English, including randomized control trials (RCTs), clinical trials, observational studies such as case-control, cross-sectional and cohort studies, whether retrospective or prospective, as well as review studies, case reports, and case series published between 2013 and 2023 that could potentially address this aim of this study, were considered eligible for inclusion. Five electronic literature databases were searched that may potentially cover the research aim: MEDLINE/PubMed, Scopus, WPRIM, LILAC, and SciELO. The search used the Health Sciences Descriptors (DeCS) and Medical Subject Headings (MeSH Terms) expressed in English through a combination of key concepts such as ‘Leukemia,’ ‘Myelogenous,’ ‘Chronic,’ ‘Hearing Loss,’ ‘Leukocytes, ‘Sense Organs.’ Next, a manual search was carried out using links to the identified articles. An independent medical librarian reviewed the search results for completeness and accuracy.
Sharing/Access information
Data was derived from the following sources:
- MEDLINE/PubMed, Scopus, WPRIM, LILAC, and SciELO. The search used the Health Sciences Descriptors (DeCS) and Medical Subject Headings (MeSH Terms) expressed in English through a combination of key concepts such as ‘Leukemia,’ ‘Myelogenous,’ ‘Chronic,’ ‘Hearing Loss,’ ‘Leukocytes, ‘Sense Organs.’
Methodology: The database was searched between January 3rd, 2023 to July 22, 2023. The search and report process followed the statement and flowchart of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). This systematic literature review of the literature was conducted by searching the MEDLINE/PubMed, Scopus, WPRIM, LILAC Sand SciELO databases. Studies published between 2013 and 2023 that met inclusion criteria were included. The Joanna Briggs Institute (JBI) Critical Appraisal Checklist was used to evaluate the quality of studies.